In 2023, the treatment success rate for previously treated tuberculosis cases in the US was at a certain level. The forecast data from 2024 to 2028 indicates a declining trend in the treatment success rates, from 74% in 2024 to 72% by 2028. Year-on-year variations show a consistent decrease of either 1% or stability at previous levels. Over this five-year period, the compound annual growth rate (CAGR) reflects an overall decrease in the treatment success rate, signaling potential challenges in treatment effectiveness or adherence.
Future trends to watch include developments in tuberculosis treatment protocols and adherence strategies, advancements in medical technology, potential shifts in public health policy, and the emergence of drug-resistant TB strains. Monitoring these factors will be crucial in predicting changes in treatment success rates beyond 2028.
